Anatara Lifesciences (ASX:ANR) said it is unlikely to achieve a statistically significant improvement in irritable bowel syndrome severity scoring system when compared to placebo in the second stage of the phase two Gastrointestinal ReProgramming-IBS trial based on preliminary analysis, according to a Monday Australian bourse filing.
It said the second stage of the trial moved into the database lock process after all participants completed the mandatory two-week follow-up period.
The final fully assessable number of participants has been reduced to 62 from 71 after the assessment of participant numbers for both compliance and entry criteria.
The second stage included a planned extension of the phase two trial, following the successful completion of stage 1 which reported on 20 patients with a greater than 50% reduction in IBS symptoms and with a safety profile confirmed.
It added that its planned anti-obesity in-vivo pre-clinical experiments are now underway following agreements with the University of Newcastle.
Its shares fell 74% in recent trading on Monday, reaching an all-time low.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。